The strongest evidence for the involvement of BCR signaling in CLL comes from the fact that BCR-signaling pathway inhibitors offer the most effective and successful treatment for CLL (reviewed in [1,2,3,4,11,12]). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.